ADCT - ADC Therapeutics

-

$undefined

N/A

(N/A)

ADC Therapeutics NYSE:ADCT ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Location: BiopOle, Epalinges, 1066, Switzerland | Website: https://www.adctherapeutics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

561.6M

Cash

194.7M

Avg Qtr Burn

-34.02M

Short % of Float

5.47%

Insider Ownership

21.36%

Institutional Own.

59.68%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ZYNLONTA (Loncastuximab Tesirine) (CD19) Details
Follicular lymphoma, Mantle cell lymphoma, Diffuse large B cell lymphoma

Approved

Update

Camidanlumab Tesirine (CD25) Details
Solid tumor/s, Cancer, Hodgkin Lymphoma

BLA

Submission

Phase 3

Data readout

ZYNLONTA (Loncastuximab Tesirine) (CD19) Details
Cancer, Blood cancer, Marginal zone lymphoma

Phase 2

Data readout

ZYNLONTA (Loncastuximab Tesirine) (CD19) Details
Cancer, Blood cancer, Diffuse large B cell lymphoma

Phase 2

Update

ZYNLONTA + Rituximab Details
Blood cancer, Follicular lymphoma

Phase 2

Update

Phase 1b

Data readout

ADCT-602 (CD22) Details
Acute lymphoblastic leukemia

Phase 1a

Data readout

Failed

Discontinued

Failed

Discontinued

ZYNLONTA (Loncastuximab Tesirine) (CD19) Details
Cancer, Diffuse large B cell lymphoma

Failed

Discontinued